Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations

被引：0
|
作者：
Tomoka Furukawa
Kanako Wakabayashi
Ai Tamura
Hiroshi Nakagawa
Yoshihiro Morishima
Yoichi Osawa
Toshihisa Ishikawa
机构：
[1] Tokyo Institute of Technology,Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology
[2] Japanese Society for the Promotion of Science (JSPS),Department of Pharmacology
[3] The University of Michigan Medical School,undefined
来源：
Pharmaceutical Research | 2009年 / 26卷
关键词：
ABCG2; endoplasmic reticulum associated degradation (ERAD); proteasome; SNP; ubiquitin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 479
页数：10
相关论文
共 50 条
  • [21] ASSOCIATION OF Q141K POLYMORPHISM OF ABCG2 GENE WITH THE EFFECTIVENESS OF URATE-LOWERING THERAPY IN PATIENTS WITH GOUT (PILOT STUDY)
    Eliseev, M.
    Chikina, M.
    Sheliabina, O.
    Cheremushkina, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1643 - 1644
  • [22] Multidrug resistance and cancer: The role of the human ABC transporter ABCG2
    Ejendal, KFK
    Hrycyna, CA
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2002, 3 (05) : 503 - 511
  • [23] Human ABC transporter ABCG2 in xenobiotic protection and redox biology
    Wakabayashi, Kanako
    Tamura, Ai
    Saito, Hikaru
    Onishi, Yuko
    Ishikawa, Toshihisa
    DRUG METABOLISM REVIEWS, 2006, 38 (03) : 371 - 391
  • [24] The C421A (Q141K) polymorphism enhances the 3′-untranslated region (3′-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2
    Ripperger, Anne
    Benndorf, Ralf A.
    BIOCHEMICAL PHARMACOLOGY, 2016, 104 : 139 - 147
  • [25] ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure
    El Biali, Myriam
    Karch, Rudolf
    Philippe, Cecile
    Haslacher, Helmuth
    Tournier, Nicolas
    Hacker, Marcus
    Zeitlinger, Markus
    Schmidl, Doreen
    Langer, Oliver
    Bauer, Martin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis
    Dong, Zheng
    Guo, Shicheng
    Yang, Yajun
    Wu, Junjie
    Guan, Ming
    Zou, Hejian
    Jin, Li
    Wang, Jiucun
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2015, 18 (04) : 382 - 391
  • [27] Histone deacetylase inhibitors mediate pharmacological rescue and increase membrane expression of ABCG2 harboring the Q141K single nucleotide polymorphism
    Bates, S. E.
    Tamaki, A.
    Ward, Y.
    Ierano, C.
    Robey, R. W.
    Hegde, R.
    To, K. K. W.
    EJC SUPPLEMENTS, 2010, 8 (07): : 176 - 176
  • [28] The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine
    Kim, Ho-Sook
    Sunwoo, Yu Eun
    Ryu, Ji Young
    Kang, Ho-Jin
    Jung, Hye-Eun
    Song, Im-Sook
    Kim, Eun-Young
    Shim, Joo-Cheol
    Shon, Ji-Hong
    Shin, Jae-Gook
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (05) : 645 - 654
  • [29] ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
    Dalbeth, Nicola
    House, Meaghan
    Gamble, Gregory
    Pool, Bregina
    Horne, Anne
    Purvis, Lauren
    Stewart, Angela
    Merriman, Marilyn E.
    Cadzow, Murray
    Phipps-Green, Amanda
    Merriman, Tony R.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S497 - S497
  • [30] Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules
    Woodward, Owen M.
    Tukaye, Deepali N.
    Cui, Jinming
    Greenwell, Patrick
    Constantoulakis, Leeza M.
    Parker, Benjamin S.
    Rao, Anjana
    Koettgen, Michael
    Maloney, Peter C.
    Guggino, William B.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (13) : 5223 - 5228
12345